GlaxoSmithKline Ending Voluntary 340B Pricing on Two Orphan Drugs

GlaxoSmithKline is ending voluntary 340B pricing for rural and cancer hospitals on its blockbuster severe asthma drug Nucala and first-line advanced ovarian cancer drug Zejula.

In a blow to rural and cancer hospitals, U.K. drug manufacturer GlaxoSmithKline (GSK) is ending voluntary 340B pricing for them on its blockbuster severe asthma drug Nucala and first-line advanced ovarian cancer drug Zejula.

Read More »

Generic-drug Maker e5 Pharma Offering Refunds for 340B Overcharges

e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021.

Generic drug maker e5 Pharma is giving 340B covered entities refunds for overcharges on six NDCs of the barbiturate phenobarbital during Q1 2021, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.

Read More »

Groups Blast PBMs’ Discrimination Against 340B Hospitals in Letters to FTC

Groups that represent or work with 340B hospitals urged the FTC to take a closer look at PBMs' alleged discriminatory business practices.

Pharmacy benefit managers’ discriminatory business practices against 340B hospitals boost PBMs’ financial bottom lines while hurting the hospitals’ mission to serve vulnerable patients, groups that represent or work with 340B hospitals and their pharmacists recently told the Federal

Read More »

NEJM Article Says HIV Prevention Should Rely Less on 340B Revenue

An opinion article in the New England Journal of Medicine says overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options. Some HIV/AIDS care providers say high drug prices are the problem, not 340B.

Overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options, “with dire consequences for [preexposure prophylaxis] PrEP access, impact, and equity,” says an opinion article published last

Read More »

BMS and Merck Announce Refunds for 340B Overcharges

BMS and Merck—both for the second time this year—are giving 340B covered entities refunds for overcharges on select products.

Drug manufacturers Bristol Myers Squibb (BMS) and Merck are giving 340B covered entities refunds for overcharges on select products, according to public notices by the companies posted on the U.S. Health Resources and Services Administration (HRSA) website.

Read More »

340B ADR Proposed Rule Remains at White House 5 Months Past Expected Publication Date

A proposed replacement for the 340B administrative dispute resolution process has been under White House review for more than six months.

A proposed replacement for the 340B administrative dispute resolution (ADR) process has been under White House review for more than half a year. It seems to be no closer to publication for notice and comment than it was

Read More »

HRSA Announces 340B Enrollment Flexibilities in Fire-Ravished New Mexico

HRSA has announced 340B program enrollment flexibilities in New Mexico, which is coping with the biggest wildfire in state history.

The U.S. Health Resources and Services Administration (HRSA) yesterday announced 340B program enrollment flexibilities in New Mexico due to the declaration of a public health emergency in the state.

Please Login or Become a

Read More »

Mallinckrodt Is the Third Drug Company This Month to Announce Refunds for 340B Overcharges

Mallinckrodt's SpecGx subsidiary is providing refunds for 340B overcharges on 22 NDCs for purchases from Q3 2019 through Q2 2020.

Drug manufacturer Mallinckrodt’s SpecGx generic pharmaceutical subsidiary is providing refunds for 340B overcharges on 22 NDCs for purchases from Q3 2019 through Q2 2020.

Please Login or Become a Paid Subscriber to View this

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report